H.C. Wainwright reiterates Cocrystal Pharma stock rating at buy
H.C. Wainwright reiterated a Buy rating and $6.00 price target for Cocrystal Pharma (COCP), citing progress in its norovirus drug trial. The stock is up 15% premarket. COCP's Phase 1b study for CDI-988 is ongoing, with primary endpoints focused on efficacy against norovirus. Analysts have varying price targets, ranging from $8 to $10. COCP also announced a new board member, Carol L. Brosgart, effective August 12, 2026.
How this was made
The 30-second read
Why it matters
Analyst reiteration and a new $6 price target suggest the market may re‑price the stock higher, especially given the +15% pre‑market move.
Market read
The news provides a fresh catalyst for COCP, potentially prompting short‑term buying pressure.
What to watch
Potential regulatory hurdles and the need for later‑stage data could temper upside.
Background
Cocrystal Pharma (NASDAQ:COCP) is a micro‑cap biotech developing a norovirus therapeutic (CDI‑988). The company recently completed Phase 1 safety studies and is now in a Phase 1b challenge trial.
Ticker impact
H.C. Wainwright reiterated a Buy rating and set a $6.00 price target after reporting progress in Cocrystal Pharma's Phase 1b norovirus trial.
likely upward pressure as investors price in the higher target and trial optimism
The rating reiteration and $6 target represent a significant upside from the $1.07 price, and trial progress is a material catalyst for this micro‑cap biotech.
Market effects
Positive signal for the infectious‑disease biotech sector as trial data advances.
U.S. biotech investors may see increased interest in early‑stage viral therapeutics.
Limited to investors tracking small‑cap biotech pipelines.
Counterpoint
The trial is still early‑stage; success is uncertain and the price target may be overly optimistic.
Key entities
- AnalystH.C. Wainwright
Equity research firm that issued the Buy rating and $6 target.
- CompanyCocrystal Pharma, Inc.
Biotech developing norovirus drug CDI‑988.
